Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX – Get Free Report) was upgraded by William Blair to a “strong-buy” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.
Separately, UBS Group assumed coverage on shares of Telix Pharmaceuticals Limited American Depositary Shares in a report on Friday, November 15th. They set a “buy” rating and a $21.00 target price on the stock.
Check Out Our Latest Report on TLX
Telix Pharmaceuticals Limited American Depositary Shares Stock Down 0.5 %
See Also
- Five stocks we like better than Telix Pharmaceuticals Limited American Depositary Shares
- What Are Dividend Achievers? An Introduction
- Tesla Investors Continue to Profit From the Trump Trade
- What is the S&P/TSX Index?
- MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally
- How to Find Undervalued Stocks
- Netflix Ventures Into Live Sports, Driving Stock Momentum
Receive News & Ratings for Telix Pharmaceuticals Limited American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals Limited American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.
